Literature DB >> 1456176

A synthetic peptide metalloproteinase inhibitor, but not TIMP, prevents the breakdown of proteoglycan within articular cartilage in vitro.

H J Andrews1, T A Plumpton, G P Harper, T E Cawston.   

Abstract

IL1-stimulated pig articular cartilage fragments were cultured in the and absence of various metalloproteinase inhibitors. Tissue inhibitor of metalloproteinases (TIMP) was unable to stop the release of proteoglycan from the cartilage. Incubation of cartilage with a potent synthetic metalloproteinase inhibitor inhibited the release of proteoglycan in a dose-dependent fashion. The results suggest that low-M(r) metalloproteinase inhibitors may have therapeutic potential in limiting connective tissue breakdown in conditions such as rheumatoid arthritis.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1456176     DOI： 10.1007/bf01987904

Source DB:  PubMed          Journal:  Agents Actions        ISSN： 0065-4299


  18 in total

1.  The impact of protein size and charge on its retention in articular cartilage.

Authors:  P L van Lent; W B van den Berg; J Schalkwijk; L B van de Putte; L van den Bersselaar
Journal:  J Rheumatol       Date:  1987-08       Impact factor: 4.666

2.  Crystallization and preliminary X-ray analysis of porcine synovial collagenase.

Authors:  L F Lloyd; T Skarzyński; A J Wonacott; T E Cawston; I M Clark; C J Mannix; G P Harper
Journal:  J Mol Biol       Date:  1989-11-05       Impact factor: 5.469

3.  Potent collagenase inhibitors prevent interleukin-1-induced cartilage degradation in vitro.

Authors:  J S Nixon; K M Bottomley; M J Broadhurst; P A Brown; W H Johnson; G Lawton; J Marley; A D Sedgwick; S E Wilkinson
Journal:  Int J Tissue React       Date:  1991

4.  Proteoglycan- and collagen-degrading enzymes from human interleukin 1-stimulated chondrocytes from several species: proteoglycanase and collagenase inhibitors as potentially new disease-modifying antiarthritic agents.

Authors:  G DiPasquale; R Caccese; R Pasternak; J Conaty; S Hubbs; K Perry
Journal:  Proc Soc Exp Biol Med       Date:  1986-11

5.  Peptide hydroxamic acids inhibit skin collagenase.

Authors:  W M Moore; C A Spilburg
Journal:  Biochem Biophys Res Commun       Date:  1986-04-14       Impact factor: 3.575

Review 6.  The effect of interleukin-1 on connective tissue metabolism and its relevance to arthritis.

Authors:  R A Bunning; H J Richardson; A Crawford; H Skjodt; D Hughes; D B Evans; M Gowen; P R Dobson; B L Brown; R G Russell
Journal:  Agents Actions Suppl       Date:  1986

7.  Effect of synthetic metalloprotease inhibitors on cartilage autolysis in vitro.

Authors:  C B Caputo; L A Sygowski; D J Wolanin; S P Patton; R G Caccese; A Shaw; R A Roberts; G DiPasquale
Journal:  J Pharmacol Exp Ther       Date:  1987-02       Impact factor: 4.030

8.  Pig catabolin is a form of interleukin 1. Cartilage and bone resorb, fibroblasts make prostaglandin and collagenase, and thymocyte proliferation is augmented in response to one protein.

Authors:  J Saklatvala; L M Pilsworth; S J Sarsfield; J Gavrilovic; J K Heath
Journal:  Biochem J       Date:  1984-12-01       Impact factor: 3.857

9.  Interleukin 1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint.

Authors:  E R Pettipher; G A Higgs; B Henderson
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

10.  Effects of inhibitors of plasminogen activator, serine proteinases, and collagenase IV on the invasion of basement membranes by metastatic cells.

Authors:  R Reich; E W Thompson; Y Iwamoto; G R Martin; J R Deason; G C Fuller; R Miskin
Journal:  Cancer Res       Date:  1988-06-15       Impact factor: 12.701
View more
  11 in total

1.  Proteolytic mechanisms of cartilage breakdown: a target for arthritis therapy?

Authors:  D J Buttle; H Bramwell; A P Hollander
Journal:  Clin Mol Pathol       Date:  1995-08

Review 2.  Matrix metalloproteinases. Novel targets for directed cancer therapy.

Authors:  A E Yu; R E Hewitt; E W Connor; W G Stetler-Stevenson
Journal:  Drugs Aging       Date:  1997-09       Impact factor: 3.923

3.  "Aggrecanase" activity is implicated in tumour necrosis factor alpha mediated cartilage aggrecan breakdown but is not detected by an in vitro assay.

Authors:  D J Buttle; A Fowles; M Z Ilic; C J Handley
Journal:  Mol Pathol       Date:  1997-06

4.  Blocking cartilage destruction with metalloproteinase inhibitors: a valid therapeutic target?

Authors:  T Cawston
Journal:  Ann Rheum Dis       Date:  1993-11       Impact factor: 19.103

5.  Stromelysin 1, neutrophil collagenase, and collagenase 3 do not play major roles in a model of chondrocyte mediated cartilage breakdown.

Authors:  L D Kozaci; C J Brown; C Adcocks; A Galloway; A P Hollander; D J Buttle
Journal:  Mol Pathol       Date:  1998-10

6.  Inhibitors of collagenase but not of gelatinase reduce cartilage explant proteoglycan breakdown despite only low levels of matrix metalloproteinase activity.

Authors:  C J Brown; S Rahman; A C Morton; C L Beauchamp; H Bramwell; D J Buttle
Journal:  Clin Mol Pathol       Date:  1996-12

7.  Identification of tissue inhibitor of metalloproteinase-2 (TIMP-2)-progelatinase complex as the third metalloproteinase inhibitor peak in rheumatoid synovial fluid.

Authors:  T E Cawston; H F Bigg; I M Clark; B L Hazleman
Journal:  Ann Rheum Dis       Date:  1993-03       Impact factor: 19.103

8.  Human shoulder tendon biopsy samples in organ culture produce procollagenase and tissue inhibitor of metalloproteinases.

Authors:  S Dalton; T E Cawston; G P Riley; I J Bayley; B L Hazleman
Journal:  Ann Rheum Dis       Date:  1995-07       Impact factor: 19.103

9.  A simple in vivo model of collagen degradation using collagen-gelled cotton buds: the effects of collagenase inhibitors and other agents.

Authors:  E H Karran; K Dodgson; S J Harris; R E Markwell; G P Harper
Journal:  Inflamm Res       Date:  1995-01       Impact factor: 4.575

10.  In vivo model of cartilage degradation--effects of a matrix metalloproteinase inhibitor.

Authors:  E H Karran; T J Young; R E Markwell; G P Harper
Journal:  Ann Rheum Dis       Date:  1995-08       Impact factor: 19.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.